Leerink Partners Strengthens M&A Team with New Strategic Hires
People | Nov 14, 2024 | Leerink Partners LLC
Leerink Partners, a prominent investment bank in the healthcare sector, has announced the strategic hiring of Grant Curry and Jason Truman to bolster its biopharma Mergers and Acquisitions (M&A) team. The two industry veterans join the firm as Senior Managing Directors under the leadership of Tom Davidson, Co-President and Co-Head of Global Investment Banking. This move aligns with Leerink Partners' ambitious plans for growth, as it marks the one-year anniversary of its management-led buyout and aims to double its pre-MBO revenue. Curry and Truman bring extensive experience from their previous roles at firms including Guggenheim Securities, Gordon Dyal & Co., Credit Suisse, and Morgan Stanley, having collectively advised on over $230 billion in transactions. Leerink Partners, known for its specialization in healthcare investment banking, continues to expand its capabilities in biopharma capital markets, leveraging its sector knowledge and broad client network. The firm's commitment to offering comprehensive advisory services is underscored by these key hires, enhancing its ability to serve biopharma clients across a range of strategic and financial objectives.
Sectors
- Healthcare Investment Banking
- Biopharmaceuticals
Geography
- United States – The primary location for Leerink Partners and the significant market for its biopharma M&A activities.
- Europe – Grant Curry's experience includes advising European clients, indicating Leerink's international reach within the biopharma sector.
Industry
- Healthcare Investment Banking – The industry pertains to the provision of financial advisory and capital raising services within the healthcare sector. Leerink Partners specializes in this area, offering M&A services and other investment banking solutions to biopharma companies.
- Biopharmaceuticals – This industry involves companies dealing with pharmaceuticals derived from biological sources. The article's focus on biopharma M&A highlights Leerink's involvement in this specific sector.
Financials
- 230 billion USD – Collective transaction advisory experience of Grant Curry and Jason Truman in M&A.
- 65 billion USD – Total advisory deals Leerink Partners has advised on since inception.
- 170 billion USD – Capital raised by Leerink Partners for its clients.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Leerink Partners | Investment Bank | Company | A specialized healthcare investment bank focusing on providing advisory services and capital raising for biopharma companies. |
| Grant Curry | Senior Managing Director | Person | A new addition to Leerink's M&A team, bringing extensive experience in biopharma M&A and activism defense. |
| Jason Truman | Senior Managing Director | Person | Recently joined the biopharma M&A team at Leerink, known for his expertise in M&A transactions. |
| Tom Davidson | Co-President and Co-Head of Global Investment Banking | Person | Oversees the global investment banking activities at Leerink Partners, including the M&A team. |
| Jeff Leerink | Chairman and CEO | Person | Heads Leerink Partners, emphasizing commitment to client service and strategic growth. |
| Prosek Partners | PR Agency | Company | Handles public relations for Leerink Partners. |
| Guggenheim Securities | Previous Employer | Company | Jason Truman's former firm, where he built the biopharma M&A practice. |
| Gordon Dyal & Co. | Previous Employer | Company | Grant Curry's former firm, where he was involved in biopharma transactions. |